| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | LCN2; 24p3; MSFI; NGAL; Lipocalin-2; p25; Siderocalin; SV40 induced 24P3 protein; Uterocalin;;NGAL |
| WB Predicted band size | 23 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human NGAL |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于Lipocalin-2抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**：*Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron*
**作者**：Flo, T.H. et al.
**摘要**：该研究揭示了Lipocalin-2(LCN2)通过结合细菌铁载体抑制病原体生长，并利用抗体实验证明其在宿主先天免疫防御中的关键作用，特别是在败血症模型中的保护机制。
---
2. **文献名称**：*Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute kidney injury*
**作者**：Mishra, J. et al.
**摘要**：作者开发了特异性Lipocalin-2抗体，用于检测急性肾损伤(AKI)患者尿液和血液中的NGAL水平，证实其作为早期AKI生物标志物的敏感性和临床实用性。
---
3. **文献名称**：*Lipocalin 2 promotes breast cancer progression*
**作者**：Yang, J. et al.
**摘要**：通过抗体验证，研究显示Lipocalin-2在乳腺癌中高表达，促进肿瘤侵袭和转移，并调控铁代谢相关通路，提示其作为治疗靶点的潜力。
---
如需具体实验细节或更多文献，可进一步补充关键词或研究场景。
Lipocalin-2 (LCN2), also known as neutrophil gelatinase-associated lipocalin (NGAL), is a 25-kDa secretory glycoprotein belonging to the lipocalin superfamily. It plays diverse roles in innate immunity, iron transport, inflammation, and cellular homeostasis. Initially identified in activated neutrophils, LCN2 is upregulated in response to bacterial infections, tissue injury, and various pathological conditions, including acute kidney injury, cancer, and metabolic disorders. Its ability to sequester bacterial siderophores links it to antimicrobial defense, while its interaction with iron-metabolizing proteins influences cellular iron homeostasis.
Anti-Lipocalin-2 antibodies are essential tools for studying its biological functions and clinical applications. These antibodies enable the detection and quantification of LCN2 in biological samples (e.g., serum, urine) via techniques like ELISA, Western blotting, and immunohistochemistry. In research, they help elucidate LCN2's dual role in promoting or suppressing disease progression, depending on context—for example, its pro-tumorigenic effects in certain cancers versus its protective role in metabolic inflammation. Clinically, LCN2 is explored as a biomarker for early kidney injury diagnosis, sepsis monitoring, and cancer prognosis. Antibodies are also investigated for therapeutic potential, such as blocking LCN2-mediated pathways in inflammatory or oncologic therapies. Challenges include ensuring antibody specificity due to structural similarities among lipocalins and optimizing cross-reactivity across species in preclinical models.
×
